Karoly Nikolich

Karoly Nikolich is a board member at Engrail Therapeutics. Karoly has also served on the boards of Chase Pharmaceuticals, Neuropore Therapies, Inc., Stanford University Medical School, Pivotal BioVenture Parnters, biOasis Technologies Inc., Circuit Therapeutics, and ExcelImmune.

At ExcelImmune, Nikolich served as chairman of the board. ExcelImmune uses human recombinant polyclonal antibodies to treat infectious diseases.

At Angiochem, Nikolich served as chairman of SAB. AngioChem is a pioneer of therapies for brain tumors and its platform enables the transport of a wide variety of therapeutic agents to the brain efficiently.

Karoly Nikolich received their PhD from Eötvös Loránd University and did their postdoctoral work in neuroscience at the University of California, San Francisco - School of Medicine. Karoly is currently a Professor of Neurology at Tulane University School of Medicine.